ABO-incompatible living-donor kidney transplantation: Study of 48 patients after desensitisation

• Published in: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia Vol. 39; no. 6; pp. 612 - 622
• Main Authors: Fernández Rivera, Constantino, Calvo Rodríguez, María, López Muñíz, Andrés, Ferreiro Hermida, Tamara, Seijo Bestilleiro, Rocío, Andón Saavedra, Concepción, Galego García, Andrea, Alonso Hernández, Angel
• Format: Journal Article
• Language: English; Spanish
• Published: Spain 01.11.2019
• Subjects: Inmunoadsorción; ABO-incompatible living-donor kidney transplant; Desensibilización; Desensitisation; Rituximab; Immunoadsorption; Trasplante renal de donante vivo ABO incompatible; Plasmaféresis; Plasmapheresis
• ISSN: 1989-2284; 2013-2514
• DOI: 10.1016/j.nefro.2019.02.010

ABO-incompatible living-donor kidney transplantation was regarded as an absolute contraindication. However, it has been carried out for years with good outcomes. Our aim was to show the results obtained with this technique in our hospital. Forty-eight patients with a mean age of 50.9±10.9 years were included. Follow-up was 44.6±30.9 months. Conditioning: rituximab 375mg/m , tacrolimus, mycophenolate mofetil or mycophenolate sodium, prednisone, plasmapheresis/immunoadsorption and intravenous immunoglobulin. Accepted IgG and IgM titres for transplantation:<1:8. Pre-process IgG titre 1:124±1:140, IgM titre 1:77±1:55. After 6±3 sessions, IgG decreased to<1:8 in 47 patients and to<1:16 in one. IgM was<1:8 in all cases. Twenty-four patients (50%) had haematoma, 7 re-intervention (14.6%), 29 (60%) required transfusion. At 5 years, acute rejection had occurred in 5 cases (8.7%), CMV infection in 9 (19.7%), BK viraemia in 5 (12.4%), post-transplant diabetes in 10 (23.4%) and lymphocele in 3 (6.4%). Patient survival was 97.1% at 5 years and graft survival 95.7% at one year and 93% at 5 years. Causes of graft loss: thrombosis (n=1); mixed rejection (n=1); and death (n=2). Serum creatinine levels were 1.4±0.4mg/dl at one and 3 years and 1.3±0.3mg/dl at 5 years. Proteinuria was 0.2±0.2g/24h at one, 3 and 5 years. ABO-incompatible living-donor kidney transplantation after conditioning with rituximab, plasmapheresis/immunoadsorption and immunoglobulins is a valid option offering excellent outcomes. There is a low incidence of acute rejection and no increase in infectious complications. An increased tendency for postoperative bleeding was found.